energy

Image: Flickr - Junichiro Aoyama

Bz-423, a mitochondrial F1F0-ATP synthase inhibitor, that has previously shown promise for the treatment of autoimmune disorders such as lupus, arthritis and psoriasis has now been shown to halt the progression of established graft-versus-host disease (GVHD) in mouse models of allogeneic bone marrow transplantation. GVHD, in which functional immune cells in the transplanted marrow mount an immunological attack on the recipient, is a common complication of allogeneic bone marrow transplantation that can cause severe organ damage and even be life-threatening. As well as demonstrating that Bz-423 can reduce GVHD clinical scores and improve survival in mice, researchers at the University of Michigan and the University of Florida have shed new light on the metabolism of alloreactive T cells.

Bz-423 structure

Bz-423

Resting lymphocytes meet their minimal demand for ATP using low rates of oxidative phosphorylation. Upon activation, normal lymphocytes meet the increased demand for ATP by dramatically increasing their rate of aerobic glycolysis which also helps to maintain high levels of antioxidants in activated cells. Data from the present study suggest that alloreactive T cells, on the other hand, rely heavily on increased oxidative phosphorylation to generate more ATP. This difference in energy generation is also seen in pathogenic T cells involved in autoimmune diseases and provides a mechanistic basis for the specific elimination of pathogenic cells by Bz-423, whilst preserving normal immune function.

The study is published in Science Translational Medicine.

Lycera Corporation has a program to develop orally bioavailable F1F0-ATP synthase inhibitors that exploit bioenergetic abnormalities in pathologically activated lymphocytes and result in the selective silencing of these cells.

Related posts:

  1. Reflux Esophagitis May Not Be Caused Directly by Acid Burn Gastroesophageal reflux (GER), or acid reflux, which occurs when the lower esophageal sphincter opens spontaneously or doesn’t close properly, is...
  2. Long-Life Immunity The primary function of the thymus is to produce mature T-cells and to implement controls to prevent auto-immunity. Lymphocyte precursors...
  3. New Role for Immune System in Osteoporosis Many reports have linked high cholesterol with osteoporosis and HMG-CoA reductase inhibitors (statins) have been proposed to reduce the risk...
  4. A Rebalancing Approach to Cystic Fibrosis Cystic fibrosis is an inherited disease that affects about 70,000 children and adults worldwide. The condition is caused by a...

Related posts brought to you by Yet Another Related Posts Plugin.

This entry was posted on Monday, January 31st, 2011 at 2:05 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

2 Responses to “Exploiting Bioenergetic Differences to Stop GVHD”
  1. Barry Bunin says:

    This was the benzodiazepine that I (Barry Bunin) synthesized first at UC Berkeley in the Ellman Group using solid phase synthesis. I still remember first scaling it up:

    http://www.linkedin.com/in/collaborativediscovery

    Glad to see it getting some news.

  2. [...] This post was mentioned on Twitter by Jay, DDO. DDO said: Exploiting Bioenergetic Differences to Stop GVHD http://bit.ly/ebgrQa [...]

  3.  
Leave a Reply